ストックスクリーナーアプリを入手
24.77
3.90%
0.93
前日終値:
$23.84
開ける：
$24.07
24時間の取引高:
42.71M
Relative Volume:
1.48
時価総額：
$5.65B
収益：
$2.35B
当期純損益:
$128.37M
株価収益率:
47.44
EPS:
0.5221
ネットキャッシュフロー:
$57.42M
1週間 パフォーマンス:
+57.37%
1か月 パフォーマンス:
+51.96%
6か月 パフォーマンス:
-55.37%
1年 パフォーマンス:
-21.46%
1日の値動き範囲:
$23.25
$24.82
1週間の範囲:
$20.97
$27.54
52週間の値動き範囲:
$13.74
$70.43
Hims Hers Health Inc Stock (HIMS) Company Profile
Compare HIMS vs TAK, ZTS, HLN, TEVA, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
24.77 | 5.65B | 2.35B | 128.37M | 57.42M | 0.5221 |
|
TAK
Takeda Pharmaceutical Co Adr
|
17.77 | 56.14B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
115.62 | 48.81B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.03 | 44.67B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
28.57 | 33.27B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
536.12 | 23.50B | 3.18B | 1.33B | 1.04B | 27.90 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-10 | アップグレード | BofA Securities | Underperform → Neutral |
| 2026-03-10 | アップグレード | Citigroup | Sell → Neutral |
| 2026-03-09 | アップグレード | Needham | Hold → Buy |
| 2026-02-24 | ダウングレード | BTIG Research | Buy → Neutral |
| 2026-01-12 | 開始されました | Evercore ISI | In-line |
| 2025-12-09 | 開始されました | Barclays | Overweight |
| 2025-10-21 | 開始されました | KeyBanc Capital Markets | Sector Weight |
| 2025-06-23 | ダウングレード | Needham | Buy → Hold |
| 2025-06-04 | 繰り返されました | Needham | Buy |
| 2025-04-29 | ダウングレード | TD Cowen | Buy → Hold |
| 2025-02-18 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2025-01-10 | ダウングレード | Citigroup | Neutral → Sell |
| 2025-01-07 | 開始されました | BTIG Research | Buy |
| 2024-12-17 | 開始されました | Morgan Stanley | Overweight |
| 2024-11-14 | ダウングレード | BofA Securities | Buy → Underperform |
| 2024-08-22 | 開始されました | Needham | Buy |
| 2024-08-09 | ダウングレード | Imperial Capital | Outperform → In-line |
| 2024-05-22 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-04-16 | ダウングレード | Jefferies | Buy → Hold |
| 2024-04-10 | 開始されました | Canaccord Genuity | Buy |
| 2024-02-28 | アップグレード | Imperial Capital | In-line → Outperform |
| 2024-02-26 | 開始されました | Leerink Partners | Market Perform |
| 2023-12-07 | 開始されました | Imperial Capital | In-line |
| 2023-07-28 | 開始されました | TD Cowen | Outperform |
| 2023-04-11 | 開始されました | Robert W. Baird | Neutral |
| 2023-02-09 | アップグレード | Jefferies | Hold → Buy |
| 2022-11-08 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-11-08 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | 開始されました | Truist | Hold |
| 2022-07-15 | 開始されました | SVB Leerink | Underperform |
| 2022-04-14 | 開始されました | Guggenheim | Buy |
| 2022-04-01 | 再開されました | Credit Suisse | Outperform |
| 2022-03-10 | 開始されました | Deutsche Bank | Hold |
| 2021-12-02 | 開始されました | Jefferies | Hold |
| 2021-11-11 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | 開始されました | BofA Securities | Neutral |
| 2021-05-20 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | 開始されました | Truist | Hold |
| 2021-03-09 | 開始されました | Credit Suisse | Neutral |
| 2021-03-02 | アップグレード | Citigroup | Neutral → Buy |
| 2021-02-17 | 開始されました | Citigroup | Neutral |
| 2021-02-12 | 開始されました | Piper Sandler | Neutral |
| 2021-02-08 | 開始されました | Tigress Financial | Buy |
すべてを表示
Hims Hers Health Inc (HIMS) 最新ニュース
Hims & Hers (HIMS) Soars 57.4% on New Deal - Insider Monkey
A Look At Hims & Hers Health (HIMS) Valuation After A Sharp 57% Weekly Share Price Move - simplywall.st
Hims & Hers posts best weekly gain after Novo deal - Seeking Alpha
OWL, HIMS, TSLA And More: 5 Stocks Investors Couldn't Stop Buzzing About This WeekOracle (NYSE:ORCL) - Benzinga
Hims & Hers Health, Inc. Class A Trade Ideas — SWB:82W - TradingView
Telehealth Giant Hims Partners with Novo Nordisk After Dropping Legal Battle - Fine Day 102.3
Hims And Hers Health Weighs Eucalyptus Deal Against Growth And Valuation Risks - simplywall.st
Weekly Market Update: Stocks Slide as Financials, Consumer Cyclicals Fall - Morningstar
Hims & Hers Stock Skyrockets Amid Novo Nordisk Partnership - StocksToTrade
Hims Shares Notch Record Week as Novo Pact Spurs Optimism - Yahoo Finance
Hims & Hers (HIMS) sees analyst optimism following Novo resolution - MSN
Hims & Hers (HIMS) Sees Analyst Optimism Following Novo Resolution - Insider Monkey
Selling pressure pushes Hims & Hers Health stock lower in today's trading - Traders Union
Hims & Hers class action alleges semaglutide GLP-1 products falsely advertised - Class Action Lawsuits
Hims shares set for record week as Novo partnership fuels optimism - Modern Healthcare
Barclays Raises PT on Hims & Hers Health (HIMS) Stock - Yahoo Finance
Hims & Hers Health stock price steadies after wild Novo week as focus shifts to margins - TechStock²
Hims shares set for best week on record after new Novo Nordisk deal - Investing.com
Hims Shares Set for Record Week as New Novo Pact Fuels Optimism - Bloomberg.com
5 Best Day Trading Stocks to Buy Now - Insider Monkey
Hims & Hers Stock Jumps After Novo Nordisk Deal. What It Means for Drugmaker - TradingView
Investor relations - HIMS Investor Relations
12 Most Shorted Stocks to Buy in 2026 - Insider Monkey
Hims & Hers Health and Novo Nordisk end lawsuit over weight loss medications - MSN
‘They Need Each Other’: Why Hims & Hers and Novo Nordisk Made Up - MedCity News
Here's Why Hims & Hers Health, Inc. (HIMS) Fell More Than Broader Market - Yahoo Finance
Hims & Hers stock takes a major hit amid multiple investigations and target cuts - StocksToTrade
Stock Market Today, March 12: Hims and Hers Health Drops After Rally Sparks Profit Taking - Yahoo Finance
Hims And Hers Benefits Aims To Deepen Member Loyalty And Engagement - simplywall.st
Hims & Hers Health, Inc. (HIMS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Hims & Hers Faces Investigation Amid Wegovy Sales Discontinuation - timothysykes.com
Hims & Hers Plunges 29.4% in Three Months: How to Play the Stock? - The Globe and Mail
Hims & Hers Drops 29.4% Over Three Months: What’s the Best Strategy for This Stock? - Bitget
Hims & Hers Health hires Kathryn Beiser as chief communications officer - Medical Marketing and Media
Should You Chase the Rally in Hims & Hers Stock Today? - Barchart.com
Is Hims & Hers Really the Growth Stock to Buy That It Appears? - Yahoo Finance
Hims & Hers Health And Novo Nordisk: A Corporate Remarriage That May Work Out Profitably - Seeking Alpha
Why Hims & Hers Health (HIMS) Stock Is Surging In Thursday's Premarket - Benzinga
Hims & Hers Soars 64% in Three Days as Novo Nordisk Deal Opens Door to GLP-1 Market - TradingKey
Hims & Hers Health stock continues rally, rises 7% in premarket trading - MSN
Obesity Drugs Are Getting Easier and Cheaper to Find - Bloomberg
Hims & Hers Health (HIMS) Stock Up 7% Premarket Thursday, On Track for Best Week Ever - CoinCentral
Trending tickers: Nebius Group, Hims & Hers, BMW, Savills and On The Beach - Yahoo Finance UK
Hims & Hers (HIMS) soars 10.3% on analyst upgrades, new deal - MSN
Hims & Hers revamps GLP-1 strategy with Novo Nordisk - TipRanks
JPMorgan Chase & Co. Significantly Reduces Stake in Hims & Hers Health Inc. - GuruFocus
Hims & Hers (HIMS) Soars 10.3% on Analyst Upgrades, New Deal - Insider Monkey
A Look At Novo Nordisk’s Valuation After Hims & Hers GLP 1 Distribution Agreement - simplywall.st
Hims & Hers (NYSE: HIMS) revamps US GLP-1 weight-loss model - Stock Titan
Lucid Tops The Most-Shorted Stock List—Here Are 9 More Short Targets - Benzinga
Hims & Hers Hires Ex-Eli Lilly Communications Chief Amid Obesity Drug Strategy Shift - GuruFocus
Hims Hers Health Inc (HIMS) 財務データ
収益
当期純利益
現金流量
EPS
1.15%
3.21%
大文字化:
|
ボリューム (24 時間):